We would like to thank Endersby et al. for their interest in our study protocol and for contributing to the discussion regarding the choice of anesthesia for hip and knee arthroplasty in a fast-track setting. 1,2 The authors provided a great summary of the emerging evidence supporting the promising newer short-acting local anesthetics (LA) in spinal anesthesia (SA), 3-5 such as mepivacaine. The prospect of earlier discharge, rapid safe mobilization, and earlier return of muscle and urinary function align well with the aims of fast-track surgery.However, as the authors state, bupivacaine remains the most widely used LA in SA for hip and knee arthroplasties. 5 Bupivacaine has also been extensively researched as part of well-established fasttrack programs, with great results. 6,7 In modern fast-track setups, bupivacaine is administered with a markedly lower dose (2 mL 0.5%) than previously (3 mL 0.5%). 8 Denmark is among the top users of daycase surgery on a national level 9 and SA is primarily performed using bupivacaine. Building of the tradition for fast-track surgery, modern day-case setups in Denmark still include bupivacaine in the regime, 10 and achieve day-of-surgery discharge for above 50% of day-case eligible patients. 11 The centers in our study currently use bupivacaine in SA, but we are re-evaluating our LA use. However, the aim for our study, was to compare the two standard methods of anesthesia for hip and knee arthroplasty used at the participating centers. Also, as bupivacaine is widely used, this improves the generalizability of our results and allows us to evaluate the current common practice in hip and knee arthroplasty anesthesia.